title: Gut microbiota disturbance during antibiotic therapy: a multi-omic approach.
abstract: It is known that the gastrointestinal tract (GIT) microbiota responds to different antibiotics in different ways and that while some antibiotics do not induce disturbances of the community, others drastically influence the richness, diversity, and prevalence of bacterial taxa. However, the metabolic consequences thereof, independent of the degree of the community shifts, are not clearly understood. In a recent article, we used an integrative OMICS approach to provide new insights into the metabolic shifts caused by antibiotic disturbance. The study presented here further suggests that specific bacterial lineage blooms occurring at defined stages of antibiotic intervention are mostly associated with organisms that possess improved survival and colonization mechanisms, such as those of the Enterococcus, Blautia, Faecalibacterium, and Akkermansia genera. The study also provides an overview of the most variable metabolic functions affected as a consequence of a β-lactam antibiotic intervention. Thus, we observed that anabolic sugar metabolism, the production of acetyl donors and the synthesis and degradation of intestinal/colonic epithelium components were among the most variable functions during the intervention. We are aware that these results have been established with a single patient and will require further confirmation with a larger group of individuals and with other antibiotics. Future directions for exploration of the effects of antibiotic interventions are discussed.
authors.affiliation: Consejo Superior de Investigaciones Científicas (CSIC); Institute of Catalysis; Madrid, Spain.
authors.forename: Manuel
authors.initials: M
authors.lastname: Ferrer
authors.affiliation: Chair of Systems and Synthetic Biology; Wageningen University; Wageningen, the Netherlands; LifeGlimmer GmbH; Berlin, Germany.
authors.forename: Vitor A P
authors.initials: VA
authors.lastname: Martins dos Santos
authors.affiliation: Institute for Clinical Molecular Biology at the Christian-Albrechts University; Kiel, Germany; Department for Internal Medicine; University Hospital Schleswig-Holstein, Campus Kiel; Kiel, Germany.
authors.forename: Stephan J
authors.initials: SJ
authors.lastname: Ott
authors.affiliation: Unidad Mixta de Investigación en Genómica y Salud de la Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO); Salud Pública; Valencia, Spain; Instituto Cavanilles de Biodiversidad y Biología Evolutiva de la Universitat de València; Valencia, Spain; CIBER en Epidemiología y Salud Pública (CIBEResp); Madrid, Spain.
authors.forename: Andrés
authors.initials: A
authors.lastname: Moya
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans; D008297:Male; D064307:Microbiota / Q000187:drug effects*; D047090:beta-Lactams / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams
keywords: antibiotic therapy; human gut microbiota; metabolomic; metagenomic; metaproteomic; metatranscriptomic